Loading…
Comparing the effects of vecuronium and cisatracurium on electrophysiologic monitoring during neurosurgery: a randomized controlled study
Background: The differences between neuromuscular blocking (NMB) drugs on the efficacy of intraoperative motor-evoked potential (MEP) monitoring have not been established through clinical study. We compared the effects of vecuronium and cisatracurium on the efficacy of intraoperative MEP monitoring....
Saved in:
Published in: | Anesthesia and pain medicine (Korean society of anesthesiologists) 2017, 12(3), , pp.213-219 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background: The differences between neuromuscular blocking (NMB) drugs on the efficacy of intraoperative motor-evoked potential (MEP) monitoring have not been established through clinical study.
We compared the effects of vecuronium and cisatracurium on the efficacy of intraoperative MEP monitoring.
Methods: We enrolled 72 patients who had undergone neurosurgery with MEP monitoring. We randomly allocated the subjects into one of two groups, in whom we maintained continuous intravenous vecuronium (Group V) or cisatracurium (Group C) infusion during the surgeries; the target partial NMB for maintenance was T1/Tc 50% (T1, first twitch of TOF response; Tc, control response of T1 before NMB drug injection). We compared the means and coefficients of variation (CV, %) of all measured MEP amplitudes and the frequencies of NMB drug dose changes.
Results: The means and CVs of MEP amplitude and latency in all four limbs did not differ significantly between the groups, although we did change the continuous NMB drug doses in group V significantly less often than in group C.
Conclusions: There were no significant differences between vecuronium and cisatracurium on the MEP variability and mean amplitudes.
However, cisatracurium needed more frequent dose changes to maintain T1/Tc 50%. KCI Citation Count: 0 |
---|---|
ISSN: | 2383-7977 1975-5171 2383-7977 |
DOI: | 10.17085/apm.2017.12.3.213 |